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DNA methyltransferase inhibitors (DNMTi) decitabine and azacytidine are approved
therapies for myelodysplastic syndrome and acute myeloid leukemia, and their
combinations with other anticancer agents are being tested as therapeutic options
for multiple solid cancers such as colon, ovarian, and lung cancer. However, the
current therapeutic challenges of DNMTis include development of resistance, severe
side effects and no or partial treatment responses, as observed in more than half of
the patients. Therefore, there is a critical need to better understand the mechanisms of
action of these drugs. In order to discover molecular targets of DNMTi therapy, we
identified 638 novel CpGs with an increased methylation in response to decitabine
treatment in HCT116 cell lines and validated the findings in multiple cancer types
(e.g., bladder, ovarian, breast, and lymphoma) cell lines, bone marrow mononuclear
cells from primary leukemia patients, as well as peripheral blood mononuclear cells and
ascites from platinum resistance epithelial ovarian cancer patients. Azacytidine treatment
also increased methylation of these CpGs in colon, ovarian, breast, and lymphoma
cancer cell lines. Methylation at 166 identified CpGs strongly correlated (|r| ≥ 0.80)
with corresponding gene expression in HCT116 cell line. Differences in methylation at
some of the identified CpGs and expression changes of the corresponding genes was
observed in TCGA colon cancer tissue as compared to adjacent healthy tissue. Our
analysis revealed that hypermethylated CpGs are involved in cancer cell proliferation
and apoptosis by P53 and olfactory receptor pathways, hence influencing DNMTi
responses. In conclusion, we showed hypermethylation of CpGs as a novel mechanism
of action for DNMTi agents and identified 638 hypermethylated molecular targets
(CpGs) common to decitabine and azacytidine therapy. These novel results suggest that
hypermethylation of CpGs should be considered when predicting the DNMTi responses
and side effects in cancer patients.
Keywords: DNA methyltransferase inhibitors, decitabine, azacytidine, anticancer treatment, olfactory receptor
pathway, alternative splicing
INTRODUCTION
DNA methyltransferase inhibitors (DNMTi) are widely used as chemical tools for hypomethylating
the genome, with an aim to understand the role of DNA methylation in multiple processes
(e.g., X-chromosome inactivation and DNA imprinting) and as an anti-cancer therapy (Minkovsky
et al., 2015; Ramos M.P. et al., 2015; Bohl et al., 2018). At present, two DNMTi drugs, decitabine and
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azacytidine, have been approved for treating patients with
myelodysplastic syndrome (MDS) and acute myeloid leukemia
(AML) (Döhner et al., 2017; Bohl et al., 2018), and are also
being tested as therapeutic options in multiple solid cancers
(Fu et al., 2011; Singal et al., 2015; Lee et al., 2018). However,
treatment response rates have remained very low in both solid
and hematological cancers patients (Derissen et al., 2013; Nervi
et al., 2015; Koch et al., 2018). At the same time, DNMTi
treatment incurs considerable side effects (e.g., bleeding, anemia,
and joint pain). Attempts are being made to improve treatment
efficacy (e.g., by testing combinations of DNMTis with other
anticancer agents) and safety (e.g., by stratifying cancer patients
into DNMTi responders and non-responders) (Nervi et al., 2015)
of the drugs. However, the precise prediction of drugs that show
synergy with DNMTi in combination as well as distinguishing the
drug responders from the non-responders are challenging tasks
and are currently compromised by our incomplete knowledge of
the drug mechanisms of action in various cancer-types (Ramos F.
et al., 2015; Wang et al., 2018).
Hypomethylation of the genome is one of the principal
mechanisms behind the therapeutic benefit of DNMTi treatment
and hypomethylated targets of the drugs (e.g., CpGs, genes,
genomic region, pathways) have been functionally well-
characterized in multiple cancer cell lines and other model
systems (Sarkar et al., 2013; Tobiasson et al., 2017; Koch
et al., 2018). However, DNMTi induced hypomethylation of
the genome is not sufficient to clearly understand DNMTis’
response and side effects (Ramos F. et al., 2015; Wang et al.,
2018), suggesting presence of additional mechanisms by which
DNMTis’ may modulate their responses. Therefore, there is a
critical need to better understand the mechanism of action of
DNMTis’ in more details, including their molecular targets in
various cancer cells. Only a few studies indicated that DNMTi
treatment can also lead to DNA hypermethylations in specific
cell types, probably due to an increased expression of DNA
methylating enzymes (Broday et al., 1999; Kastl et al., 2010;
Chowdhury et al., 2015). For example, Kastl et al. (2010) reported
an increase in the mRNA level of DNMT1, DNMT3a, and
DNMT3b genes in docetaxel-resistant MCF7 cells, as compared
to drug-sensitive cells when treated with decitabine. However,
we currently lack the information of the genomic location and
function of molecular targets in the cancer genome that can resist
the DNA demethylation and show hypermethylation in response
to DNMTi treatment.
In the present work, we hypothesized that DNMTi treatment
causes hypermethylation in the genome, and therefore we
systematically investigated the extent of hypermethylated CpGs,
their location, and biological role by analyzing cell line
and primary tumor data. Since colon cancer tissue has
revealed silencing of various tumor suppressor genes due to
hypermethylation (Huidobro et al., 2012), and especially the
HCT116 cell line has widely been utilized to study DNA
methylation and its role in regulating gene expression in colon
cancer (De Carvalho et al., 2012; Yang et al., 2014), we selected
HCT116 cell line as our primary disease model to discover
novel hypermethylated CpGs. We validated the findings in a
panel of 53 other cancer cell lines (e.g., lymphoma, colon,
ovarian, and breast cancer), as well as in bone marrow cells of
2 primary leukemia patients, 2 PBMCs and 2 ascites samples of
ovarian cancer patients. There was a significant correlation in the
methylation of a fraction of identified CpGs and corresponding
genes’ expression in HCT116 cell line indicating that the
identified hypermethylated CpGs are clinically functional. Our
work aims at initiating the search of hypermethylation in the
response to DNMTi treatment in cancer cells and tissues as
a novel mechanism by which one could predict in future the
therapeutic and adverse effects of DNMTis in multiple cancer
sub-types (i.e., stratified medicine), or even in individual cancer




To identify CpGs with increased methylation after decitabine
treatment, we re-analyzed the DNA methylation (Illumina 450K
platform, GSE51810) data from the study of Yang et al. (2014),
where colon cancer HCT116 cells were treated with decitabine
(0.3 mM) for 72 h. Cells were maintained in McCoy’s 5A
medium, supplemented with 10% fetal bovine serum along with
1% penicillin/streptomycin after drug treatment, and followed
through 5, 14, 24, 42, and 68 days. The increase in DNA
methylation in HCT116 cells were validated using methylation
data from the study of Han et al. (2013) (Illumina 450K,
GSE41525), where HCT116 and T24 bladder cancer cell lines
were treated with 0.3 and 1 µM of decitabine, respectively, for
24 h, and Illumina 450K assay was performed for both untreated
and decitabine-treated cells. We also tested the increase in DNA
methylation of identified CpGs using DMSO (as mock treatment)
and decitabine-treated (0.06 µM for 72 h) MCF7 breast cancer
cells using data generated by Leadem et al. (2018) (Illumina 450K
platform, GSE97483). These cells were cultured in Minimum
Essential Medium (MEM) with 10% fetal bovine serum).
Further, we validated our findings identified in cell lines using
DNA methylation data from primary bone marrow mononuclear
cells (Illumina 450K platform, GSE20945-GPL13534) from two
freshly diagnosed acute myelogenous leukemia patients (IDs 1107
and 1307) and one healthy control (BM) (Tsai et al., 2012). The
frozen primary cells were thawed and cultured in Poietics HPGM
supplemented with 50 ng/ML human thrombopoietin, 25 ng/mL
stem cell factor, 50 ng/mL Flt-3 ligand, 10 ng/mL recombinant
human IL-3, 10 ng/mL recombinant human IL-6, 10 ng/mL
recombinant human GM-CSF and 1 ng/mL recombinant human
G-CSF, as specified in Tsai et al. (2012). These cells have been
treated with 10 nM of decitabine or PBS (control) for 72 h with
daily medium change. DNA methylation for patient 1307 was
assessed at day 3 as well as day 14 and for patient 1107 at day
7. We also analyzed genome wide DNA methylation (Illumina
Infinium 27K Beadchip, GSE31826) profile of 14 peripheral
blood mononuclear cells (PBMC), 8 tumor biopsies and 6 ascites
samples from recurrent, platinum resistant epithelial ovarian
cancer patients, before and after treatment with decitabine (Matei
et al., 2012). Patients have been treated with decitabine (Eisai) at
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10 mg/m2 given intravenously daily for 5 days. The methylation
for each sample was measured before treatment at day 1 (control)
and after decitabine treatment at day 8 (treated). The comparison
of treated and control samples was done using the paired
Wilcoxon non-parametric test on the basis of 16 common CpGs
(out of 638) with hypermethylation.
We extended our discovery analyses also to another DNMTi
inhibitor, azacytidine, by re-analyzing DNA methylation data
(Illumina 450K, GSE45707) for untreated and azacytidine-treated
(5 mM for 72 h) lymphoma U937 cell line. We further re-analyzed
additional methylation (Illumina 450K platform, GSE57342) and
gene expression data (GSE57343) from 26 breast cancer cell
lines (MDA231, SKBR3, HCC38, ZR7530, HCC1937, CAMA1,
MDA415, HCC1500, BT474, EFM192A, MDA175, MDA468,
MDA361, HCC1954, BT20, ZR751, HCC1569, EFM19, T47D,
MDA453, MCF7, HCC1187, HCC1419, MDA436, SUM149, and
SUM159), 12 colorectal cancer cell lines (SW48, HCT116, HT29,
RKO, SW480, Colo320, Colo205, SW620, SNUC-1, CACO-2, SK-
CO1, and Colo201), and 13 ovarian cancer cell lines (TykNu,
CAOV3, OAW28, OV2008, ES2, EF27, Kuramochi, OVKATE,
Hey, A2780, OVCAR3, OVCAR5, and SKOV3) measured after
mock treatment and 0.5 µM azacytidine treatment for 72 h
(Li et al., 2014). The cells were cultured and maintained under
recommended conditions for each cell line (Li et al., 2014).
To investigate the alteration in methylation status of
identified probes in cancerous tissue and their role in gene
expression regulation, TCGA level 3 HumanMethylation 450K
data and normalized RNA-seq gene expression profiles for
colon adenocarcinoma (COAD) patients (both tumor and
adjacent healthy tissue samples) were downloaded using the
FireBrowse tool1.
In all the analysis, methylation status at a CpG site was
measured as beta value (β), which is the ratio of the methylated
probe intensity and the overall intensity (sum of methylated
and unmethylated probe intensities designed for a particular
CpG in 450K beadchip). β ranges from 0 to 1, indicating no
methylation (β = 0) to complete methylation of the CpGs (β = 1).
We performed appropriate quality control of the published
data before their downstream analysis as described previously
(Giri et al., 2017). As a part of quality control, we removed
all the CpGs with missing values and CpGs assessed by probes
that have a tendency of cross-hybridization, as specified in the
supplementary file of Chen et al. (2013). To remove any possible
bias due to design differences in the type of probes (the type
I and type II probes) present in the Illumina 450K platform,
we performed BMIQ normalization (Teschendorff et al., 2013)
to the DNA methylation data from the TCGA samples before
correlation and differential methylation analysis. All other data
processing was done using local inbuilt commands in R.
Identification of Probes With Increased
Methylation in HCT116 Cell Line
We calculated the difference in methylation level of CpGs before
and after treatment with decitabine in HCT116 cell line at
day 5 in data from Yang et al. (2014) (GSE51810). CpG that
1http://gdac.broadinstitute.org/
showed an increase in β-value of greater than or equal to 0.10
(1β ≥ 0.10) between untreated control and decitabine treated
HCT116 cells were identified as hypermethylated CpGs. The
population doubling time reported by Yang et al. (2014) was used
for correlation analysis with methylation level of identified CpGs.
We estimated population doubling time as 24 h for untreated cells
and 34, 38, 31, 28, 26, and 25.5 h for treated cells at time points of
5, 14, 24, 42, and 68 days.
Gene Expression Data Analysis
We downloaded gene expression profiles of untreated control
and decitabine treated HCT116 cell lines at 5, 14, 24, and
42 days (GSE51811, Illumina HumanHT-12 V4.0 expression
beadchip) from the same study of Yang et al. (2014). The
downloaded data were log2-transformed and normalized using
robust spline normalization (RSN) method as implemented
in the lumi package in R (Du et al., 2008). Pearson corre-
lation between methylation and gene expression across different
time points in HCT116 cell line was assessed using the
cor.test function of R.
Normalized RNA-seq data of TCGA colon adenocarcinoma
patients downloaded from FireBrowse tool1 were further
normalized using voom function in the limma package
(Ritchie et al., 2015), and these data were Z-transformed
before the differential and correlation analyses. Wilcoxon non-
parametric test was used to identify differentially methylated and
differentially expressed genes between TCGA adenocarcinoma
tumors and adjacent healthy tissue samples (FDR < 0.05).
Only those adenocarcinoma samples that had both DNA
methylation and gene expression information were used for the
correlation analyses.
In order to find the possible reasons for absence of hyper-
methylation by low dose treatment with azacytidine in breast
cancer cell lines, we extracted and compared the gene expression
DNMT3A, DNMT3B, DNMT1, and DNMTL across 26 breast
cancer, 12 colorectal cancer, and 13 ovarian cancer cell lines at
day 3 (after azacytidine treatment) using gene expression data
from Li et al. (2014) (GSE57343). We downloaded the processed
gene expression data of azacytidine treated cells normalized to
mock treated respective controls and compared across cell lines
of different tissue types.
Gene Annotation and Pathway
Enrichment Analysis
Identified CpGs were annotated for their location in the genome
based on annotation file provided by Illumina2. Gene ontology
and pathway enrichment analysis of the genes corresponding
to CpGs with hypermethylation were done using GeneCodis
(Tabas-Madrid et al., 2012). Statistical enrichment was assessed
by FDR corrected p-values from hypergeometric test for separate
ontology terms and pathways. GENEMANIA (Zuberi et al., 2013)
was used to construct and visualize the interaction network
between genes and the transcription factor regulating them.
2ftp://ussd-ftp.illumina.com/downloads/ProductFiles/HumanMethylation450/
HumanMethylation450_15017482_v1-2.csv
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FIGURE 1 | Decitabine treatment increases DNA methylation levels of a subset of CpGs. (A) Scatter plots showing DNA methylation patterns of 638 differentially
methylated CpGs between untreated control cells (x-axis) and decitabine-treated cells (y-axis) at various time points in the study of Yang et al. (2014). (B) Violin plot
showing the median methylation level (horizontal line) and distribution patterns (density and IQR) of the identified 583 CpGs in untreated and 0.3 µM
decitabine-treated HCT116 cells after 24 h in the study of Han et al. (2013). The statistical significance was assessed using the non-parametric Wilcoxon test.
∗∗∗p < 0.0005.
Key term enrichment analysis for the genes corresponding to
CpGs was done using DAVID (Huang Da et al., 2009).
RESULTS
DNMTi Treatment Increases Methylation
of a Small Portion of the CpGs
After quality control, we re-analyzed a total of 369886 CpGs
across the genome of HCT116 colon cancer cells from Yang et al.
(2014), and identified hypermethylation (1β ≥ 0.10) of 638 CpGs
in 393 unique genes after 5 days of decitabine treatment (0.3 mM
for 72 h), as compared to untreated cells (Figure 1A). Most of the
loci were hypomethylated in the genome (median β = 0.18), and
after decitabine treatment, a median increase of 0.12 (1β = 0.12,
p < 0.0005) in methylation level was observed for these sites. The
detailed list of the identified CpGs is provided in Supplementary
Table 1. Change in methylation at 34 of the identified CpGs
were strongly correlated (Pearson correlation coefficient > 0.80,
FDR <0.05) with the population doubling time of HCT116
cell lines after decitabine treatment (Supplementary Table 2),
indicating that methylation at a fraction of identified CpGs affects
proliferation and growth of cancer cells. However, most of the
identified sites loss their hypermethylation by day 10 (Figure 1)
suggesting that the observed hypermethylation is transient. Re-
analysis of another methylation data for HCT116 cell line from
the Han et al. (2013) study validated our finding, as we found a
corresponding increase in methylation level (median 1β = 0.09)
at 583 common CpGs after decitabine treatment (0.3 µM for
24 h) (Figure 1B). These results indicate that the increase in
DNA methylation at most of the identified sites starts as early
as 24 h after the DNMTi treatment and lasts up to at least
day 5. The result suggests that there are CpGs that not only
resist the demethylation in response to DNMTi but also show
transient hypermethylation.
Further, we also tested the effect of decitabine on identified
differentially methylated CpGs in a bladder cancer cell line
(T24). An increase in median DNA methylation levels (median
1β = 0.14, p < 0.0005) at 616 common CpGs was observed after
the drug treatment (1 µM for 24 h) in T24 cells (Figure 2A) in
contrast to a significant decrease in the methylation level of other
CpGs present in the 450K beadchip (median 1β = −0.14) as
shown in Supplementary Figure 1. However, we did not observe
any increase in methylation level of 590 common identified
CpGs (median 1β = −0.01, p < 0.0005) in breast cancer
MCF7 cell line treated with 0.06 µM of decitabine for 72 h
(Figure 2B). Replication of the results in multiple cancer cell
lines indicates that hypermethylation in the cancer genome is
a common effect of decitabine treatment that can contribute to
DNMTis’ response.
To study the effect of another DNMT inhibitor, azacytidine, on
methylation of identified CpGs, we next re-analyzed 450K data
from 52 pan-cancer cell lines. We found a significant increase
in methylation of identified CpGs in 9 out of 13 ovarian cancer
cell lines (median 1β > 0.03), 3 out of 26 breast cancer cell
lines (median 1β > 0.01), and in 9 out of 12 colon cancer cell
lines (median 1β > 0.02), and in 1 lymphoma cell line (U937,
median 1β > 0.06) after azacytidine treatment (Figures 3A–D).
Validation of the observed hypermethylation at identified target
CpGs in multiple cancer types (bladder, ovarian, breast, and
lymphoma cancer cell lines) suggests that hypermethylation in
the genome is a shared phenomenon in response to multiple
DNMTi agents and that the degree of the hypermethylation is
cancer- and cell line-specific.
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FIGURE 2 | Increase in methylation of identified CpGs is cell line-specific. (A) Methylation level of 616 identified probes common in untreated and decitabine-treated
(1 µM for 24 h) bladder cancer T24 cell line. An increase in median DNA methylation levels (median 1β = 0.14) at 616 common CpGs was observed after the drug
treatment. (B) Methylation level of 590 identified probes common in mock (DMSO) and decitabine-treated (0.06 µM for 72 h) breast cancer MCF7 cell line. We
observed a smaller decrease in methylation level (median 1β = –0.01, p < 0.005) when the cells were treated with lower dose (0.06 µM) of decitabine in MCF7 cell
lines. The statistical significance was assessed using the non-parametric Wilcoxon test. ∗∗∗p < 0.0005.
FIGURE 3 | Azacytidine treatment increases methylation of identified sites in a subset of cell lines. Change in median methylation level of identified CpGs in
(A) 13 ovarian cancer cell lines (B) 26 breast cancer cell lines, and (C) 12 colon cancer cell lines. The bar plot represents the difference in the median methylation
level of identified CpGs between cells treated with 0. 5 µM azacytidine (test group) or carboplatin (mock group) after 72 h. (D) Scatter plot showing the distribution of
methylation level of identified probes in untreated (control) and treated cells (5 mM of azacytidine for 72 h) in U937 lymphoma cell lines. The statistical significance
was assessed using the non-parametric Wilcoxon test. ∗p < 0.05, ∗∗p < 0.005.
Identified CpGs Show Trend of
Hypermethylation in AML and
Ovarian Cancer Primary Cells
To investigate the CpGs identified in the HCT116 colon cancer
cells in primary patient samples, we analyzed hypermethylation
of identified CpGs in mononuclear cells from bone marrow
sample of two primary AML patients (Figure 4). Increase in
DNA methylation (1β = 0.06, p = 4.68 × 10−7 at day 7) was
observed at the identified CpGs after decitabine treatment in
the bone marrow mononuclear cells of one patient (ID 1107)
but not of the healthy control (median 1β = −0.02, p = 0.26
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FIGURE 4 | Pirate plot show the median methylation level (horizontal colored line) and distribution pattern (mean ± standard error as vertical black line) of the
identified 638 CpGs in untreated and treated (10 nM of decitabine) mononuclear cells from a healthy bone marrow (BM) sample and two primary leukemia patient
samples (IDs 1307 and 1107), based on the data from the study of Tsai et al. (2012). DNA methylation assay for the patient 1307 was performed at days 3 and 14.
For the patient 1107, the assay was performed only at day 7. The median methylation level is indicated in each plot. The statistical significance was assessed using
the paired non-parametric Wilcoxon test. NS, not significant. ∗∗∗p < 0.0005.
at day 3), suggesting that hypermethylation in response to
DNMTi might be specific to cancerous cells but not to healthy
cells (Figure 4). We also observed trend of hypermethylation
at identified CpGs (median 1β = 0.06, p = 0.76) at day 3 in
another primary leukemia patient (ID 1307) that was lost by day
14 (median 1β = −0.01, p = 2.13 × 10−35) (Figure 4). This
result again suggests that hypermethylation at identified sites
after DNMTi treatment is transient also in primary leukemia
cancer cells, similarly as was observed in the HCT116 cell line
model. Further, significant hypermethylation was observed in
2 out of 14 PBMCs (P2 and P3) and 2 out of 6 ascites (A1 and A2)
samples of platinum resistant epithelial ovarian cancer patients
treated with decitabine as compared to untreated paired samples
(Supplementary Figure 2). Validation of the hypermethylation
at identified CpGs in the PBMCs and ascites samples treated
with clinically used dose of decitabine (10 nM) further confirm
our findings. We did not either observe hypermethylation in any
of the eight tumor biopsy samples (Supplementary Figure 2)
from the ovarian cancer patients which might be because of the
requirement of higher dose of drug to result in the same effect in
solid cancer as compared to PBMC and ascites samples.
The Methylation of Identified CpGs
Correlates With Expression of
Corresponding Genes
To discover the functional role of methylation in differentially
methylated CpGs, we correlated DNA methylation level of
identified CpGs and expression levels of the corresponding genes
at multiple time points (0, 5, 14, 24, and 42 days) measured
in HCT116 cell line after decitabine treatment. The distribution
of correlation coefficients for 130 CpGs in promoter and 200
CpGs in gene body area has been shown in Figure 5A. A strong
correlation (|r| ≥ 0.80) between the gene expression and DNA
methylation profiles was observed at 27% of loci (166 CpGs in 153
genes) in HCT116 cells, out of them, 47 CpGs corresponding to
44 genes were nominally significant (p < 0.05) (Supplementary
Table 3) indicating that observed hypermethylations affect
cellular function by altering gene expression in cancer cell lines.
The correlation between gene expression and DNA methylation
suggests that the increase in DNA methylation is functional
and causes transcriptional changes that affects cellular processes
(e.g., cell proliferation).
Genes Corresponding to the Identified
CpGs Show Differential Expression in
Cancerous Tissue
We further investigated the pathological relevance of the
increased methylation at identified CpGs using DNA methylation
and gene expression profile of normal and cancerous tissue
from TCGA colon adenocarcinoma patients. Out of 638 CpGs
discovered in HCT116 cell line, we extensively investigated the
methylation of CpGs in promoter and gene body area in TCGA
data as methylations at these locations have a major effect
on gene expression (Yang et al., 2014; Koch et al., 2018). We
selected 53 promoter CpGs and 78 gene body CpGs showing a
strong methylation-expression correlation (| r| ≥ 0.8) in HCT116
cell lines and their methylation levels were compared between
cancerous (n = 273) and adjacent healthy tissues (n = 19)
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FIGURE 5 | DNA methylation at hypermethylated sites affects gene expression in HCT116 cell lines and TCGA colon adenocarcinoma samples. (A) Histogram
depicts density of Pearson correlation coefficients (PCCs) between DNA methylation and gene expression for 130 CpGs in promoter region (left panel) and 200 CpGs
in gene body area (right panel). The PCCs were calculated using DNA methylation of a CpGs and the expression level of corresponding genes at day 0 (untreated
cells), 5, 14, 24, and 42 days after decitabine treatment. Further, 53 promoter CpGs and 78 gene body CpGs showing a strong methylation-expression correlation
(|r| ≥ 0.8) in HCT116 cell lines were selected and their methylation levels were compared between cancerous (n = 273) and adjacent healthy tissues (n = 19) samples
in TCGA colon cancer data. A significant difference in methylation level (FDR < 0.05) was observed at 38 promoter and 73 gene body CpGs. (B) Heatmap showing
the methylation level of these 38 promoters (left panel) and 73 gene body (right panel) CpGs in healthy tissue and colon cancer tissue. Subsequently, the expression
level of genes corresponding to CpGs showing significant methylation differences in TCGA colon cancer data were compared and 19 genes corresponding to
significant CpGs in promoter region, and 38 genes corresponding to the significant CpGs in gene body region were found differentially expressed (FDR < 0.05).
(C) Heatmap showing the expression profile of genes with significant differences in adjacent healthy tissue (n = 19) and colon cancer samples (n = 273).
samples in TCGA colon cancer data. This analysis revealed
differential methylation of 38 promoter CpGs and 73 gene body
CpGs in cancer tissue (Figure 5B and Supplementary Table 4).
Subsequently, the expression level of genes corresponding to
CpGs showing significant methylation differences in TCGA colon
cancer data were compared and the analysis revealed significant
difference (FDR < 0.05) in expression of 19 and 38 genes
corresponding to differentially methylated CpGs at promoter and
gene body area in colon cancer tissue respectively (Figure 5C
and Supplementary Table 5). The analysis suggests that DNMTi
treatment increases methylation at CpGs that involved in the
pathology of cancer and hence such alteration can contribute to
the therapeutic response of the drugs.
Genes With Increased Methylation Are
Enriched in Cancer-Related Pathways
and Are NFAT, LEF1, and MAZ-Regulated
We next investigated the functions of the genes corresponding
to the identified CpGs using the GeneCodis (v2) gene set
enrichment analysis tool. Gene ontology enrichment analysis
revealed that five out of the 10 (50%) most significant
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FIGURE 6 | Gene ontology (GO) and pathway enrichment analyses of genes corresponding to differentially methylated CpGs. (A) Top-10 most significantly enriched
cellular processes are shown as a bar plot. The lengths of the bars denote the number of genes present in each of the top GO categories. (B) Pie-chart showing the
significantly enriched pathways for the genes. The number of genes present in each pathway group is shown along with the hypergeometric test p-value corrected
for multiple testing as implemented in the DAVID tool. (C) The keywords enrichment analysis for the genes is shown as a bar chart. The length of the bar represents
the number of genes enriched for each keyword, the FDR-corrected p-value is shown at the top. ∗FDR < 0.05; ∗∗FDR < 0.005; ∗∗∗FDR < 0.0005.
TABLE 1 | Top five transcription factor enriched in gene set corresponding to identified 638 CpGs and its regulated genes.
Transcription
factor Genes (N) FDR Regulated genes
NFATC1 47 1.48 × 10−8 SLIT3, RORA, SYT10, CNTNAP2, SCN3A, MRPL28, ADAMTSL1, CTNND2, ESR1, PPM1B, PDE4D, RARB,
OPCML, SNX15, PRKD2, ID3, PTPRO, ADCY2, CUL3, DMD, ITM2C, KLF12, BCOR, CTNND1, SGCD,
ACACA, HDAC6, POGK, AUTS2, PAX3, DLG2, SLC6A5, SOX5, DLC1, ANTXR1, NGFRAP1, LSAMP, GRM8,
CACNA2D3, ETS1, S100A10, ADAMTS17, KCNH5, ARHGAP6, KCNMA1, MAP7, KCNN2
LEF1 59 2.10 × 10−8 PDCD10, NRXN1, SLIT3, RORA, YWHAZ, COX7B, SYNPR, SCN3A, SORCS1, TMSB4X, ADAMTSL1, NXN,
CLSTN2, ZNF8, CNTN6, MAGED2, WHSC1L1, GMPR2, PDE4D, ABCF2, RARB, CNKSR2, TIA1, SMARCA1,
SFRP2, OPCML, WDFY3, MBTD1, CACNA1E, PTPRO, MCTS1, DMD, KLF12, CTNND1, SGCD, ACACA,
POGK, OXCT1, TAF1, PAX3, SLC6A5, SOX5, 1, SIX4, GPC6, DLC1, GTF2A2, TLE3, GAB2, TMSL3,
CACNA2D3, ETS1, BZW1, ADAMTS12, CD160, TCERG1L, KCNH5, ARHGAP6, NR2F1
MAZ 51 4.07 × 10−8 PDCD10, SLIT3, SV2B, RORA, YWHAZ, CNTNAP2, SORCS1, PRKCI, CTNND2, ACCN2, ESR1, MAGED2,
HRK, FKBP2, RARB, CNKSR2, SSR1, SMARCA1, SFRP2, PRKD2, UBE2L3, PTPRF, ID3, DMD, ITM2C,
KLF12, P4HA1, BCOR, RGS7, CTNND1, DUSP6, POGK, TAF1, LYPLA2, AUTS2, DLG2, SOX5, SIX4, DLC1,
TLE3, PRDM16, NGFRAP1, POLR1D, ARVCF, BZW1, THRAP3, TRRAP, ZNRF1, KCNH5, KCNMA1, NR2F1
OCT1 16 1.49 × 10−7 NRXN1, NR2C2, SCN3A, PDE4D, RARB, DMD, KLF12, DUSP6, SOX5, DLC1, TLE3, GAB2, TMSL3,
TCERG1L, IRX2, NR2F1
MEF2 27 2.32 × 10−7 HIPK1, CTNNA1, NRXN3, ESR1, PPM1B, SLC12A1, SMARCA1, OPCML, WBP5, ADCY2, CUL3, DMD,
KLF12, P4HA1, CTNND1, SGCD, DLG2, SOX5, GLG1, NELL2, GRM8, CACNA2D3, ETS1, CIAO1,
ADAMTS12, AGTPBP1, NR2F1
FDR-corrected p-values from the hypergeometric test are shown in the table.
GO processes (FDR = 0.05) were related to transcription
regulation, which is one of the key functional role of DNA
methylation in order to control gene expression (Figure 6A).
Notably, the list of enriched genes included well-known
oncogenes, such as AFF3, CTNND2, ELK4, ESR1, PAX3,
TRRAP, and WHSC1L1. The pathway enrichment analysis
revealed that olfactory transduction and p53 signaling pathway
were overrepresented (FDR = 0.05) in the gene set with
increased methylation (Figure 6B), and alternating splicing
was enriched as the major keyword (fold enrichment = 1.27,
FDR = 0.000132, Figure 6C). Identified CpGs were also
enriched in the enhancer region (p = 3.36 × 10−4) of the
genomes (Supplementary Figure 3).
Furthermore, enrichment analysis among the transcription
factors regulating these identified genes revealed that 59
genes were regulated by lymphoid enhancer-binding factor
1 (LEF1) (p = 2.1 × 10−8, Table 1 and Supplementary
Figure 4A), 51 genes by MYC Associated Zinc Finger Protein
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(MAZ) (p = 4.07 × 10−8, Table 1 and Supplementary
Figure 4B) and 47 of genes were regulated by the nuclear
factor of activated T-cells (NFATC1, p = 1.48 × 10−8,
Supplementary Figure 4C). Enrichment of genes in
cancer-related pathways, especially in the p53 tumor
suppressor pathway and the olfactory pathway, suggests
that hypermethylation in the identified sites affects cancer cell
proliferation and apoptosis.
DISCUSSION
Our study indicates that a clinically feasible dose of decitabine
(0.3 to 300 µM) treatment causes a transient increase in DNA
methylation level of a small fraction of CpGs in the colon
cancer genome. The use of 3-day exposure with such doses
in vitro produces a quick increase in DNA methylation that may
reflect the immediate response of cells to external stimuli. The
transient increase in methylation (that vanishes 10 days after
treatment) at identified targets also suggests that the response
is mainly a temporary alteration of transcript level of certain
genes, rather than permanent shut down or enhancement of
their expression.
The further study of the hypermethylation in primary bone
marrow mononuclear cells from AML patients, peripheral
blood cells and ascites from epithelial ovarian cancer patients
indicated that hypermethylation of subsets of the identified
CpGs is an important mechanism behind DNMTi effects
against primary cancer cells, which, as expected, varies
across patients and cancer types. Additionally, the absence
of hypermethylation in normal bone marrow mononuclear
cells indicates that the hypermethylation is limited to cancerous
tissues and cell lines. However, a future study exploring
hypermethylation at identified CpGs in pre- and post-
treated cancerous tissue types (e.g., kidney, skin, brain), in
comparison to corresponding healthy cells, is needed to
detail the tissue-specificity of the hypermethylation at the
identified CpGs.
We did not observe hypermethylation in case of breast
cancer MCF7 cell lines treated with low dose (0.06 µM) of
decitabine, nor in 20 out of 26 breast cancer cell lines treated
with 5 mM of azacytidine (low dose), even though the same
dose of azacytidine was sufficient to hypermethylate the CpGs
in colon and ovarian cancer cell lines. It suggests that lower
doses of DNMTi agents are not sufficient to hypermethylate
the identified CpGs in all the cancer cell lines, which could
be because of their molecular peculiarities. For example, lower
change in expression level of DNA methylating enzymes
DNMT3A was observed in breast cancer cell lines 3 days
after azacytidine treatment, as compared to colon and ovarian
cancer cell lines (Supplementary Figure 5). DNMT3A is a
de novo methylating enzyme and have been associated with
CpGs hypermethylation phenotype in AML (Spencer et al.,
2017). Further, the expression level of DNMT3A and DNMT3B
have been associated with sensitivity to decitabine cytotoxic
response in embryonic cells (Oka et al., 2005), testicular germ
cell tumor (Beyrouthy et al., 2009) and have also shown
to be predictive of decitabine treatment response in patient-
derived xenograft model for triple negative breast cancer (Yu
et al., 2018). Differences in expression of DNMT enzymes,
together other molecular differences (e.g., genetic mutations or
epigenetic differences) may resists breast cancer cells against
the hypermethylation in response to DNMTi at a lower dose.
However, a detailed mechanistic study will be needed to
understand the absence of hypermethylation in breast cancer
cells in relation with DNMT3A or DNMT3B levels and other
molecular heterogeneity.
Additionally, genes associated with identified CpGs were
enriched among olfactory receptor and p53 pathways. P53
pathway regulates DNA repair and apoptosis in HCT116
cells (Li et al., 2015), and there is growing evidence for the
involvement of olfactory receptor pathway in cancers of non-
olfactory tissues such as prostate (Neuhaus et al., 2009), lung
(Giandomenico et al., 2013; Kalbe et al., 2017), and colon
cancers (Morita et al., 2016). For instance, olfactory receptor
OR51B4 is highly expressed in colon cancer HCT116 cells and the
activation of the receptor by its ligand (Troenan) inhibited cell
proliferation and apoptosis by phosphorylation of p38, mTOR,
and Akt kinases (Weber et al., 2017). The available literature
therefore suggests that identified hypermethylation can affect
colon cancer cells proliferation and apoptosis through olfactory
receptor pathway. However, a detailed mechanistic study is
warranted to decipher the exact role of hypermethylation at
identified CpGs in cellular growth through p53 and olfactory
receptor pathways.
Further, enriched transcription factor LEF1 is implicated
in tumorigenesis and cancer cell proliferation, migration,
invasion, and stemness in multiple cancer (e.g., colorectal cancer,
AML, oral squamous cell carcinoma) (Santiago et al., 2017).
Moreover, the methylation at a fraction of CpGs was positively
correlated with the population doubling time of HCT116 cells
indicating the role of identified CpGs in cell division, and
proliferation. Enrichment of genes among the cancer-related
pathways involved in cell proliferation and apoptosis suggests a
non-random selection of CpGs for hypermethylation in order
to alter the cellular dynamics (e.g., population doubling time).
We consider that increased in methylation at identified CpGs
can contribute to the drug response in multiple cancer types
partly by altering the cell division rate. The methylation levels
at identified CpGs could be useful to design better treatment
strategies (e.g., predicting the DNMTi responders and non-
responders), and to understand side effects due to higher drug
dose (e.g., the increase in DNA methylation at identified CpGs
could be an indicator for degree of possible toxic effect). These
novel findings therefore warrant further analyses in a number of
cancer types using either pre-clinical animal studies or clinical
treatment data from cancer patients with baseline molecular
profiles available.
There are multiple reasons to suggest that at least one key
mechanism underlying the anti-tumor responses to DNMTi
treatment may involve hypermethylation of specific genes in
cancer cells. First, we showed an increase in DNA methylation
at identified CpGs in more than one type of cancer cells.
Second, as defined for an epigenetic change, these sustained
Frontiers in Pharmacology | www.frontiersin.org 9 April 2019 | Volume 10 | Article 385
fphar-10-00385 April 17, 2019 Time: 16:22 # 10
Giri and Aittokallio Decitabine/Azacytidine Increases DNA Methylation
changes persist for significant periods of time (at least more than
5 days) after a transient, subsequently withdrawn, drug exposure
(in this case 72 h). Third, the expression patterns for a subset of
the genes are different between cancer and normal tissue types.
Importantly, these changes are induced by drug doses that do
not acutely kill cells and, thus, allow the transient alterations in
gene methylation patterns to act on emerging molecular changes
to cells after DNMTi therapy.
In summary, our findings suggest that DNMTi mediates its
therapeutic effect through a complex mechanism of action, and
therefore a generalized pattern for the activity is challenging to
find as DNMTi treatment causes hypermethylation at certain
loci and hypomethylation at others. Hence, the effects of
DNMTi on cancer tissues should be analyzed at the individual
gene level, rather than at the entire genomic level, and
separately for each tissue type and even for each cancer
patient. Further, any attempt to predict DNMTi response
should also incorporate the hypermethylated targets of the
drugs along with the hypomethylated targets of the drugs.
However, a functional mechanistic study in more advanced
model systems and several human tissue types will be required
for further revealing how the increase in methylation at
identified loci alters treatment response and the pathological
burden of disease. We hope that these identified targets
associated with hypermethylation have broad implications
for further research on DNMTi response mechanisms in
multiple cancer types.
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